Viridian Therapeutics
VRDN
72 hedge funds and large institutions have $459M invested in Viridian Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
31% more funds holding
Funds holding: 55 → 72 (+17)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
0% less capital invested
Capital invested by funds: $460M → $459M (-$1.24M)
10.87% less ownership
Funds ownership: 107.09% → 96.22% (-11%)
Top Buyers
Top Sellers
VRDN Hedge Fund Activity: Q1 2022 in Review
72 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2022, worth a combined $459M — down 0.27% from $460M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VRDN positions and 3 closed out — a net gain of 17 holders — while 24 added to existing stakes and 16 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $13.4M. The largest seller was Frazier Management, exiting entirely with an estimated $29.8M sold.
- 72 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2022, up from 55 in Q4 2021.
- Funds reported $459M of Viridian Therapeutics stock for Q1 2022, down 0.27% quarter-over-quarter.
- 20 funds opened new Viridian Therapeutics positions in Q1 2022 and 3 closed out, a net change of +17 holders.
- The largest Viridian Therapeutics buyer in Q1 2022 was Cormorant Asset Management, an estimated $13.4M added.
- The largest Viridian Therapeutics seller in Q1 2022 was Frazier Management, an estimated $29.8M sold.
Based on aggregated 13F filings for Q1 2022.